5 Dividend Aristocrats® So Good You'll Never Want to Sell

Want increasing lifetime income? Learn my method to easily screen for stocks, and discover 5 Dividend Aristocrats to get you just that--plus the inspiring story of a retail investor and turned a $180 investment into a $7 million windfall.

Stock prices used were the market prices of April 13, 2025. The video was published on April 15, 2025.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Dividend Aristocrats® is a registered trademark of Standard & Poor's Financial Services LLC.

Should you invest $1,000 in Abbott Laboratories right now?

Before you buy stock in Abbott Laboratories, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Abbott Laboratories wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $518,599!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $640,429!*

Now, it’s worth noting Stock Advisor’s total average return is 794% — a market-crushing outperformance compared to 153% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.

See the 10 stocks »

*Stock Advisor returns as of April 14, 2025

Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Abbott Laboratories and Linde. The Motley Fool recommends Lowe's Companies and Sherwin-Williams. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.